Roche’s implant for chronic eye disorder wins FDA approval

Tajammul Pangarkar
Tajammul Pangarkar

Updated · Oct 22, 2021

SHARE: is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
Advertiser Disclosure

At Scoop, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Scoop. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

October 22, 2021

By Amruta Khandekar and Bhanvi Satija

(Reuters) -Swiss drugmaker Roche Holding AG said on Friday the U.S. health regulator approved its eye implant for patients with a chronic disorder causing blurred vision, giving them an alternative to receiving monthly eye injections with existing treatments.

Roche’s Susvimo is a surgically implantable device intended to treat wet age-related macular degeneration (wet AMD), a disorder which occurs when abnormal blood vessels leak fluid or blood into an area near the retina called the macula.

The device is designed to continuously deliver a customized version of the company’s drug ranibizumab, branded as Lucentis, which is an anti-VEGF therapy.

Anti-vascular endothelial growth factor (anti-VEGF) therapies, the current standard of care for wet AMD, work against a protein said to play a key role in the disease and require patients to receive eye injections as often as monthly to preserve vision.

Susvimo, which is intended for those who have previously responded to at least two anti-VEGF injections, needs to be taken only twice a year.

More than 98% of patients treated with the device were able to go six months before needing a refill in the company’s late-stage study last year.

“This device will be a first-of-its-kind alternative to the current standard of care injections for patients with wet AMD,” Levi Garraway, Roche’s chief medical officer, said in an interview with Reuters before the approval.

The device has an exchange mechanism that simultaneously refills a new batch of medicine while the residual drug is removed, Garraway added.

UBS analyst Michael Leuchten estimates that the U.S. market size for AMD is roughly $3.5 billion.

Susvimo is also being reviewed for the treatment of wet AMD by the European Medicines Agency (EMA), the company said.

Lucentis was first approved for wet AMD in the United States in 2006. Other anti-VEGF therapies include Regeneron Pharmaceuticals’ Eylea and Novartis’ Beovu.

(Reporting by Amruta Khandekar and Bhanvi Satija; Editing by Aditya Soni and Maju Samuel)

Source Link Roche’s implant for chronic eye disorder wins FDA approval

Tajammul Pangarkar

Tajammul Pangarkar

Tajammul Pangarkar is a CMO at Prudour Pvt Ltd. Tajammul longstanding experience in the fields of mobile technology and industry research is often reflected in his insightful body of work. His interest lies in understanding tech trends, dissecting mobile applications, and raising general awareness of technical know-how. He frequently contributes to numerous industry-specific magazines and forums. When he’s not ruminating about various happenings in the tech world, he can usually be found indulging in his next favorite interest - table tennis.